trending Market Intelligence /marketintelligence/en/news-insights/trending/hnkielo-wcekodu9q6ctgq2 content esgSubNav
In This List

Idera Pharmaceuticals implements 1-for-8 reverse stock split

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Idera Pharmaceuticals implements 1-for-8 reverse stock split

Idera Pharmaceuticals Inc.'s board approved a 1-for-8 reverse split of its stock, effective July 27.

The split-adjusted common shares will trade on the Nasdaq Capital Market starting July 30.

Shareholders of the Cambridge, Mass.-based drug developer previously approved the reverse stock split, which reduced Idera Pharmaceuticals' number of issued and outstanding shares to about 27.2 million, from about 217.4 million.

Computershare Trust Co. NA is acting as exchange agent and transfer agent for the reverse stock split.